C9073 – Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
HCPCS Level II code · C codes: Outpatient PPS (Hospital Outpatient)
HCPCS codeC9073
- Long description
- Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Short description
- Brexucabtagene autoleucel ca
- Pricing indicator
53Statute- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1EOther drugs- Cross reference
- Q2053
- Added
- January 1, 2021
- Last change
- April 1, 2021 – No change
- Termination date
- March 31, 2021
Frequently asked questions
What is HCPCS code C9073?
C9073 is a HCPCS Level II code for brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose. It was discontinued on March 31, 2021.
Does Medicare cover C9073?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby C codes
- C9065 – Injection, romidepsin, non-lyophilized (e.g. liquid), 1mg
- C9066 – Injection, sacituzumab govitecan-hziy, 2.5 mg
- C9067 – Gallium ga-68, dotatoc, diagnostic, 0.01 mci
- C9068 – Copper cu-64, dotatate, diagnostic, 1 millicurie
- C9069 – Injection, belantamab mafodontin-blmf, 0.5 mg
- C9070 – Injection, tafasitamab-cxix, 2 mg
- C9071 – Injection, viltolarsen, 10 mg
- C9072 – Injection, immune globulin (asceniv), 500 mg
- C9074 – Injection, lumasiran, 0.5 mg
- C9075 – Injection, casimersen, 10 mg
- C9076 – Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- C9077 – Injection, cabotegravir and rilpivirine, 2mg/3mg
- C9078 – Injection, trilaciclib, 1 mg
- C9079 – Injection, evinacumab-dgnb, 5 mg
- C9080 – Injection, melphalan flufenamide hydrochloride, 1 mg
- C9081 – Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.